Is the era of Monsanto tyranny finally coming to an end? These numbers seem to affirm the biotech giant is failing

‘Share prices — plummeting. Royalties — cut. Consumer opinion — in the toilet. Governments — fed up. Monsanto’s earnings represent the writing on the wall, but the company’s glory days are nearing an end[1] for many reasons ranging from farmer and consumer resistance to government crackdowns on GMO products and even Monsanto’s best-selling chemical product, glyphosate. Monsanto’s days are about as numbered as a fruit fly’s.
If we were to ascertain Monsanto’s financial health by their stock price alone, you could safely say that they are suffering. The company recently slashed its 2016 earnings forecast from the $5.10-$5.60 per share it had forecast in December, to $4.40-$5.10, claiming that the reduction was due to a lagging strength in the U.S. dollar — but there’s much more to the picture.’
Read more: Is the era of Monsanto tyranny finally coming to an end? These numbers seem to affirm the biotech giant is failing